8-K: Avanos Medical Reports Mixed Q4 and Full-Year 2024 Results, Cites Transformation Progress

Avanos Medical announces Q4 and full-year 2024 results, highlighting 5% organic growth in Q4 and a focus on transformation initiatives, but also reports a significant net loss due to a goodwill and intangibles impairment charge.

Summary

• Avanos Medical reported a 3.6% increase in fourth-quarter net sales from continuing operations, reaching $179.6 million.
• Full-year net sales from continuing operations grew by 2.2% to $687.8 million.
• The company experienced a significant fourth-quarter diluted loss per share of $8.63, compared to earnings of $0.24 per share in the prior year, largely due to a $436.7 million non-cash impairment charge.
• Adjusted fourth-quarter diluted earnings per share improved to $0.43 from $0.36 in the previous year.
• Full-year diluted loss per share was $8.40, compared to a loss of $0.21 in the prior year, but adjusted diluted earnings per share improved to $1.35 from $1.03 in 2023.
• Fourth-quarter free cash flow was $53.1 million, a significant improvement from the $3.4 million outflow in the same period last year.
• Full-year free cash flow increased to $82.9 million from $14.6 million in 2023.
• Net debt stood at $27.0 million as of December 31, 2024, compared to $80.3 million the previous year.
• The company expects 2025 net sales to be between $665 million and $685 million, with adjusted diluted earnings per share between $1.05 and $1.25.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positive aspects like improved free cash flow and adjusted EPS, the significant net loss due to the impairment charge and the cautious outlook for 2025 temper overall optimism.

Positives

• Fourth-quarter free cash flow significantly improved to $53.1 million from an outflow of $3.4 million in the prior year.
• Full-year free cash flow increased substantially to $82.9 million from $14.6 million in 2023.
• Adjusted diluted earnings per share for the fourth quarter improved to $0.43 compared to $0.36 in the prior year.
• Adjusted EBITDA for the full year increased to $107.6 million from $98.9 million in the prior year.
• Net debt decreased to $27.0 million from $80.3 million in the prior year.

Negatives

• The company reported a significant fourth-quarter net loss of $397.0 million due to a $436.7 million non-cash goodwill and intangibles impairment charge.
• Fourth quarter diluted loss per share from continuing operations was $8.63 compared to diluted earnings per share of $0.24 per share a year ago.
• Full-year diluted loss per share was $8.40, compared to a loss of $0.21 in the prior year.

Risks

• The company expects a challenging market environment for some product categories in 2025.
• Currency headwinds are expected to impact 2025 results.
• There is an anticipated pause in margin improvements in 2025.
• The company's forward-looking statements are subject to various risks and uncertainties, including economic conditions, pricing pressures, supply chain disruptions, and regulatory changes.

Future Outlook

Avanos expects 2025 net sales to be between $665 million and $685 million, and adjusted diluted earnings per share to be between $1.05 and $1.25. The company anticipates a challenging market environment and currency headwinds, leading to a pause in margin improvements in 2025, but expects to reignite margin expansion in 2026.

Management Comments

• Michael Greiner, Avanos' interim chief executive officer, stated that they are pleased with the fourth quarter results, which delivered 5% organic growth and continued execution on each of their transformation initiative priorities.
• Greiner also noted that the company generated $83 million of free cash flow and $108 million of adjusted EBITDA for the full year and currently has net debt of approximately $20 million.
• Greiner commented that the 2025 guidance reflects a challenging market environment for some product categories, as well as currency headwinds.

Industry Context

Avanos Medical operates in the medical device industry, which is subject to regulatory scrutiny, technological advancements, and competitive pressures. The company's focus on transformation initiatives and portfolio optimization aligns with industry trends towards specialization and efficiency. The EU MDR compliance costs reflect the increasing regulatory burden in the medical device sector.

Comparison to Industry Standards

• Comparing Avanos' performance to companies like Medtronic, Boston Scientific, and Stryker, which also operate in the medical device space, reveals that Avanos' revenue growth is modest.
• The significant impairment charge indicates potential challenges in specific product lines, particularly the Hyaluronic Acid (HA) portfolio, which may lag behind industry leaders in terms of innovation or market share.
• However, the improvement in free cash flow and reduction in net debt are positive signs, suggesting better financial management compared to some peers struggling with debt burdens.

Stakeholder Impact

• Shareholders will be concerned about the net loss and impairment charge, but may be encouraged by the improved free cash flow and adjusted EPS.
• Employees may face uncertainty due to the transformation process and potential restructuring.
• Customers may see changes in product offerings as the company focuses its portfolio.
• Creditors will likely view the reduced net debt positively.

Next Steps

• The company plans to execute on its internal investment and other capital allocation priorities in 2025 and beyond.
• Avanos will host a conference call to discuss the results.

Key Dates